[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368063-105":59,"doc-detail-368063-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","unleashing-the-potential-role-of-tumor-associated-nk-cells-as-a-novel-immunotherapeutic-target-in-triple-negative-breast-cancer","Unleashing the potential role of tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer","","Triple-negative breast cancer (TNBC) is the most common malignancy among women globally, and TNBC accounts for 10–20% of cases. Despite advances in immunotherapy, therapeutic benefit remains limited, particularly in immunodeficient TNBC subtypes. Tumor-associated NK cells (TaNKs) have not been defined in TNBC. This study uses single-cell transcriptomics to characterize TaNKs across cancers, showing profound functional exhaustion, reduced cytotoxicity, and heightened stress responses that impair immune surveillance. Bulk RNA-seq links higher TaNK abundance with poor prognosis. Machine learning yields a TaNK feature score (TaNKFS) based on six genes with strong prognostic power and limited response to immune checkpoint inhibitors when TaNKFS is high. Deep learning-based screening and molecular docking propose twelve TaNKFS-targeting candidate compounds, supported by synergy predictions for combination regimens, establishing TaNKs as a biomarker and guiding novel therapeutic strategies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unleashing-the-potential-role-of-tumor-associated-nk-cells-as-a-novel-immunotherapeutic-target-in-triple-negative-breast-cancer/368063/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unleashing-the-potential-role-of-tumor-associated-nk-cells-as-a-novel-immunotherapeutic-target-in-triple-negative-breast-cancer/368063.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study in TNBC?","Question",{"text":112,"@type":113},"To characterize tumor-associated NK cells (TaNKs) in triple-negative breast cancer and determine how they can inform diagnosis, prognosis, and therapeutic strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were TaNKs characterized and what functional changes were observed?",{"text":117,"@type":113},"Single-cell transcriptomics was used to profile TaNKs, revealing broad distribution across cancers and marked functional impairment, including diminished cytotoxicity and increased stress responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What is TaNKFS and how does it relate to prognosis and immunotherapy response?",{"text":121,"@type":113},"TaNKFS is a machine learning-derived feature score built from six genes that quantifies TaNK levels and predicts poor prognosis in TNBC; high TaNKFS cases show minimal benefit from immune checkpoint inhibitors.",{"name":123,"@type":110,"acceptedAnswer":124},"How were candidate drug compounds identified and what additional analysis was performed?",{"text":125,"@type":113},"Deep learning-based drug screening and high-throughput molecular docking identified twelve candidate TaNKFS-targeting compounds, and synergy prediction suggested multiple effective combination regimens.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368063,1790219346,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Pang et al. Breast Cancer Research (2026) 28:11 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-02182-8](https://doi.org/10.1186/s13058-025-02182-8)  \nRESEARCH Open Access  \nUnleashing the potential role   \nof tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer  \nJianyu Pang1,3,4, Yongzhi Chen1, Hui Wang1, Yuheng Tang1, Qi Qi1, Yingjie Sun1, Silin Zhong5, Shuxiong Luo6, Jianglin Wu6, Limin Xu3,4*, Xuhong Zhou2* and Wenru Tang1*  \nAbstract  \nBreast cancer is the most prevalent malignancy among women worldwide, with triple-negative breast cancer (TNBC) comprising 10–20% of cases. Although immunotherapy has recently emerged as a promising treatment, its efficacy remains limited in immunodeficient subtypes such as TNBC. Tumor-associated NK cells (TaNKs), an immunologically exhausted NK cell subset, have not yet been characterized in TNBC. Elucidating the TNBC tumor microenvironment through TaNKs may therefore provide novel diagnostic and therapeutic insights. Here, we employed single-cell transcriptomics to characterize TaNKs, which are broadly distributed across cancers. TaNKs displayed profound functional impairment, with diminished cytotoxicity and heightened stress responses, thereby compromising immune surveillance. Bulk RNA-seq analysis revealed that elevated TaNKs abundance correlated with poor prognosis in TNBC patients. Using machine learning, we established a TaNKs feature score (TaNKFS) incorporating six genes (HSPA1B, TUBB2A, BAG3, NR4A2, IER2, and MYADM), which demonstrated strong prognostic value and effectively quantified TaNKs levels in TNBC. Notably, immune checkpoint inhibitors showed minimal benefit in cases with high TaNKFS. Furthermore, deep learning-based drug screening and high-throughput molecular docking identified twelve candidate compounds targeting TaNKFS, including six clinically available agents (Staurosporine, Bexarotene, Cyclophosphamide, Vancomycin, Heroin, and Fluorouracil) . Synergy prediction further suggested multiple effective combination regimens. In summary, this study delineates the role of TaNKs in TNBC, establishes a prognostic biomarker, and proposes novel therapeutic strategies integrating machine learning and deep learning approaches.  \nKeywords Triple-negative breast cancer, Tumor-associated NK cells, scRNA-seq, Prognosis, Combination therapy with targeted drugs  \n*Correspondence:  \nLimin Xu [xulimin@cuhk.edu.cn](xulimin@cuhk.edu.cn)[ ](xulimin@cuhk.edu.cn)Xuhong Zhou [zhouxuhong@ynucm.edu.cn](zhouxuhong@ynucm.edu.cn)[ ](zhouxuhong@ynucm.edu.cn)Wenru Tang [20080059@kust.edu.cn](20080059@kust.edu.cn)  \n1Laboratory of Molecular Genetics of Aging and Tumor, Medical School, Kunming University of Science and Technology, Kunming, Yunnan, China  \n2Yunnan University of Chinese Medicine, Kunming, Yunnan, China 3School of Medicine, The Chinese University of Hong Kong, Shenzhen, China  \n4Shenzhen Futian Biomedical Innovation R&D Center, The Chinese University of Hong Kong, Shenzhen, China  \n5State Key Laboratory of Agrobiotechnology, School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China  \n6Dongguan Traditional Chinese Medicine Hospital, Dongguan, Guangdong, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’","cbCaijpjkMp7LwII","https://ap.wps.com/l/cbCaijpjkMp7LwII","pdf",3357049,16,"English","# Introduction\n## Breast cancer and TNBC background\n## Immunotherapy limitations in TNBC\n## Tumor microenvironment needs\n## Natural killer (NK) cells overview","[{\"question\":\"What is the main goal of this study in TNBC?\",\"answer\":\"To characterize tumor-associated NK cells (TaNKs) in triple-negative breast cancer and determine how they can inform diagnosis, prognosis, and therapeutic strategies.\"},{\"question\":\"How were TaNKs characterized and what functional changes were observed?\",\"answer\":\"Single-cell transcriptomics was used to profile TaNKs, revealing broad distribution across cancers and marked functional impairment, including diminished cytotoxicity and increased stress responses.\"},{\"question\":\"What is TaNKFS and how does it relate to prognosis and immunotherapy response?\",\"answer\":\"TaNKFS is a machine learning-derived feature score built from six genes that quantifies TaNK levels and predicts poor prognosis in TNBC; high TaNKFS cases show minimal benefit from immune checkpoint inhibitors.\"},{\"question\":\"How were candidate drug compounds identified and what additional analysis was performed?\",\"answer\":\"Deep learning-based drug screening and high-throughput molecular docking identified twelve candidate TaNKFS-targeting compounds, and synergy prediction suggested multiple effective combination regimens.\"}]","Unleashing the potential role of tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer | PDF",1790174789,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f20a80d049a66eacfd316d93ea2eb080.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/143e69a119a9f42ced04c78389678015.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00012fd2d41c500681f299d1054cbd8b.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a65e3a9008b7b88d3e55acae8dd8627.webp",980,1306]